Projects are delivered by a team of highly experienced drug development experts utilising their extensive network of academic links. The company's flexible service model is built from more than a decade of listening to customers, devising customer-centric solutions, and helping them drive breakthrough clinical development studies leveraging Catalyst's expert teams and innovative technologies.Д¬atalyst is a portfolio company of NovaQuest Capital Management, LLC, a leading healthcare and life sciences investment firm.ДЄptus Clinical is a clinical contract research organisation that specialises in the design, conduct and delivery of early phase clinical studies with a particular focus in oncology, rare diseases, cell and gene therapies. Prior to Thornburg Investment Management, Christopher served as a Vice President and Portfolio Manager for Putnam Trust, a Division of The Bank of New York Asset Management, from 2001-2005 where. With more than 700 staff across 35 countries, the company provides multi-therapeutic global resourcing and functional services through Catalyst Flex and a full-service oncology CRO offering through Catalyst Oncology. Although this is Catalyst's third M&A transaction, it is its first international union that will accelerate and expand the companies' geographic reach greatly.Д¬atalyst is a clinical development organization providing highly customizable clinical research solutions to the global biopharmaceutical industry through two established solutions: Catalyst Flex and Catalyst Oncology. visiting The value of investments may go down as well as up in response to general market conditions and. The clinical research organization joined forces with Triangle Biostatistics in 2019, and then with Ce3 in 2020. Catalyst will also work to leverage Aptus' strategic site relationships integrating them into its own site network spanning North America and Europe. 'We firmly believe Aptus Clinical and Catalyst are better together and look forward to combining our decades of experience in developing and delivering high quality clinical trials to support our combined organisation to become a significant global provider of innovative clinical research solutions.'Д¬ombined headcount for the unified company will now exceed 800 staff members. 'We are proud to partner with Catalyst to strengthen our shared commitment to delivering cutting edge science to patient populations who are in desperate need of new therapies', said Aptus Clinical CEO, Dr. Additional studies outside the Oncology therapeutic area will be delivered under the Catalyst Flex solution and operating models. Simple, fair flat fees for unbiased financial planning and guided DIY investing. Together the companies, operating as Catalyst Oncology, will continue to deliver on a portfolio of more than 100 active oncology studies via a network of 500 keenly involved investigator sites. Formed in 2014 by three former AstraZeneca clinical development experts, Aptus Clinical has rapidly established itself as a specialist CRO offering flexible clinical research solutions in oncology, cell and gene therapies and rare diseases.

Aptus investments